Patient preferences for stratified medicine in psoriasis: a discrete choice experiment*

Dalal, Garima; Wright, Stuart; Vass, Caroline; Davison, Niall J; Stichele, Geert Vander; Smith, Catherine; Griffiths, C.E.M.; Payne, Katherine

doi:10.1111/bjd.20482

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A quantitative survey was designed and launched for completion in a sample of pet owners from Canada, France, Japan, New Zealand, the UK, and the US, with a target sample size of n = 250 per region ( n = 1500 total), consistent with previous preference research studies seen in the published literature [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

Section: Methodsmentioning

confidence: 99%

Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey

Wright,

Hillier,

Lambert

et al. 2024

Animals

View full text Add to dashboard Cite

Oclacitinib is an oral therapy indicated for pruritus associated with allergic or atopic dermatitis in dogs. This study sought to assess pet owners’ perceptions of the relative convenience and value of the conventional film-coated formulation and the chewable formulation. A quantitative discrete-choice experimental methodology was applied, comparing (conventional, film-coated) oclacitinib versus chewable oclacitinib using unbranded treatment profiles. Initially, a qualitative interview phase with pet owners and veterinarians was conducted to develop detailed treatment profiles. Subsequently, pet owners participated in a quantitative survey. Overall, 1590 pet owners provided survey responses. Most respondents (62%) reported having experienced challenges administering tablet-based therapies to their dog(s). Half of all respondents (52%) had experience administering flavoured or chewable tablets to their dog. Comparing oclacitinib and chewable oclacitinib (with or without associated costs), the majority of the respondents preferred the chewable formulation in all regions across short-term and long-term scenarios (≥58%; all p < 0.05). The current research is one of few survey-driven studies for treatment preferences in companion animal medicine. Veterinarians may offer chewable or palatable treatment options where available, with potential positive impacts on convenience, compliance, outcomes, quality of life, and the human–animal bond.

show abstract

Section: Methodsmentioning

confidence: 99%

Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey

Wright,

Hillier,

Lambert

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

“…Evidence regarding infection risk and types or course of infections among biologic users is necessary, as it may guide treatment choice and treatment decisions in case of infections (e.g., continuing or interrupting treatment). Predicting infection risk seems also important from patients' perspectives 7 . The COVID‐19 pandemic resulted in attention to the risk of RTI in psoriasis patients on biological therapies, as the risk of RTI might relate to susceptibility to SARS‐CoV‐2 infections.…”

Section: Introductionmentioning

confidence: 99%

“…Predicting infection risk seems also important from patients' perspectives. 7 The COVID-19 pandemic resulted in attention to the risk of RTI in psoriasis patients on biological therapies, as the risk of RTI might relate to susceptibility to SARS-CoV-2 infections. RTI are the most frequently reported adverse events (AEs) among biologic users in trials and registries.…”

Section: Introductionmentioning

confidence: 99%

Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

Schoot

Groenewoud²,

Gelder³

et al. 2022

JEADV Clinical Practice

View full text Add to dashboard Cite

Background: Limited real-world studies are available comparing infection risk between biologics for psoriasis.Objectives: The primary aim was to determine the differential effect of currently available biologics on the risk of respiratory tract infections (RTI) among psoriasis patients in a real-world setting. Secondary aims were to explore the differential risk of all types of serious infections (SI) between biologics and to provide an early overview of SARS-CoV-2 infections during the pre-vaccine era. Methods: Crude incidence rates of RTI and SI were calculated per 100 patient-years (PY) per biologic using prospective BioCAPTURE data. Negative Binomial Regression modeling was used to explore the risk of RTI. Frailty Cox proportional hazards modeling was used to estimate hazard ratios for the risk of the first SI. Confounders adjusted for both models were selected by a directed acyclic graph. A post hoc exploratory analysis of SARS-CoV-2 infection incidence rates during 2020 was performed. Results: We included 714 patients with 1325 treatment episodes (3607.7PY between 2005 and 2020), in which 2224 RTI and 63 SI occurred. Among RTI, 1.3% were serious. The crude incidence rates were 61.7 (95% confidence interval [CI]: 59.1-64.3) per 100PY for RTI, and 1.8 (95% CI: 1.4-2.2) per 100PY for SI. Confounder adjusted analyses showed no differential risk of RTI between adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab. For SI, no differential risk was found between biologics either. Extended single-center data showed 3.8 (95% CI: 2.2-6.1) SARS-CoV-2 infections per 100PY in 2020. Conclusions: Confounder adjusted analyses showed no differential risks of RTI or SI between included biologics (adalimumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab and guselkumab) in a prospective psoriasis patients cohort. In general, absolute numbers of all types of SI were low.

show abstract

“…The article by Dalal et al. published here 1 points to an important first step in the research needed to manage treatment outcomes for patients with psoriasis. Understanding patients’ views on the information that could be offered when discussing treatment options can help make the clinical encounter more efficient.…”

mentioning

confidence: 99%

“…The article by Dalal et al. published in this issue of the BJD , ‘Patient preferences for stratified medicine in psoriasis: a discrete choice experiment’, 1 discusses how having a variety of treatment options offers opportunities to improve overall patient wellbeing. The article highlights the essential role of patient preference information in achieving this objective.…”

mentioning

confidence: 99%

Stratified psoriasis treatment plans: why is patient preference information needed?

Gonzalez

Reed

2021

Br J Dermatol

View full text Add to dashboard Cite

CMN', 'colour of CMN', 'texture of CMN' and 'satellite naevi number'; (ii) quality of life: 'emotional distress'; (iii) neoplasm: 'presence of melanoma'; (iv) neurology: 'neurological symptoms and signs'; (v) adverse events: 'wound problems of the CMN' and 'scar problems'; and, for research only, (vi) pathology: 'molecular characteristics'. Nine of ten outcomes were redundant for both patient care and research.This raises the question of whether two distinct COS are needed for this condition. In contrast, outcomes for other clinically relevant domains such as neuroimaging to rule out neurocutaneous melanocytosis and psychological functioning were not included in the final set of outcomes.The past two steps of the OCOMEN project are undoubtedly important milestones in the journey towards a uniform approach to CMN as a condition with high variability in its clinical features and a paucity of data. However, the most difficult step is still looming ahead: to define a core outcome measurement set based on specific measurement instruments. This endeavour is not entirely novel as several classification schemes have been proposed for CMN in the past. 4 Within the OCOMEN initiative, Fledderus et al. 3 agreed on size of the lesion, number of satellite naevi, colour and texture as outcomes for the domain 'skin appearance'. These parameters were also part of a consensus-based scheme for the categorization of CMN published previously by an interdisciplinary panel of experts. 5 In the next step, we will see how the COS of the OCOMEN initiative will differ from existing recommendations, and what additional value it will generate for physicians and patients. In particular, measuring the domains and outcomes relating to extracutaneous findings such as emotional distress or neurological symptoms and signs can add significant novelty and fill existing gaps as they are not sufficiently considered in current categorization schemes.

show abstract

Patient preferences for stratified medicine in psoriasis: a discrete choice experiment*

Cited by 6 publications

References 36 publications

Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey

Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey

Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry

Stratified psoriasis treatment plans: why is patient preference information needed?

Contact Info

Product

Resources

About